Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Market Cap ₹ 51,192 Cr.
- Current Price ₹ 506
- High / Low ₹ 531 / 330
- Stock P/E 21.5
- Book Value ₹ 173
- Dividend Yield 1.19 %
- ROCE 16.6 %
- ROE 13.8 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 17.8%
Cons
- The company has delivered a poor sales growth of 7.68% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5,263 | 6,358 | 7,224 | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 14,404 | 15,265 | 17,237 | |
4,177 | 5,228 | 6,021 | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,013 | 11,923 | 13,378 | |
Operating Profit | 1,086 | 1,130 | 1,203 | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,391 | 3,342 | 3,860 |
OPM % | 21% | 18% | 17% | 20% | 25% | 20% | 24% | 23% | 20% | 24% | 22% | 22% |
49 | 32 | 30 | 45 | 112 | 127 | 111 | 183 | -264 | -231 | 2,581 | -422 | |
Interest | 183 | 169 | 90 | 68 | 53 | 45 | 91 | 194 | 342 | 159 | 127 | 130 |
Depreciation | 158 | 185 | 201 | 287 | 292 | 373 | 539 | 599 | 696 | 670 | 713 | 723 |
Profit before tax | 794 | 809 | 942 | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,331 | 5,084 | 2,585 |
Tax % | 14% | 15% | 11% | 18% | 8% | 8% | 24% | 22% | 21% | 8% | 10% | 23% |
Net Profit | 681 | 690 | 836 | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 |
EPS in Rs | 6.37 | 6.38 | 7.85 | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 |
Dividend Payout % | 24% | 24% | 23% | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% | 31% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 7% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 6% |
3 Years: | 18% |
TTM: | 8% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 7% |
3 Years: | 14% |
1 Year: | 34% |
Return on Equity | |
---|---|
10 Years: | 19% |
5 Years: | 16% |
3 Years: | 16% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | |
Reserves | 2,484 | 2,842 | 3,337 | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 |
2,289 | 2,918 | 2,700 | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,608 | 4,221 | 1,195 | |
1,548 | 1,512 | 1,847 | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,165 | 6,421 | 7,046 | |
Total Liabilities | 6,423 | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,756 |
2,857 | 3,026 | 3,124 | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,253 | 11,591 | |
CWIP | 484 | 736 | 892 | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 661 | 1,130 |
Investments | 24 | 114 | 87 | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 |
3,058 | 3,498 | 3,885 | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,488 | |
Total Assets | 6,423 | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,756 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
511 | 603 | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,104 | 2,689 | |
-1,200 | -682 | -438 | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | 1,137 | 1,171 | |
860 | 286 | -529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | |
Net Cash Flow | 171 | 207 | -64 | 178 | 99 | 756 | -3 | -811 | 399 | -90 | 2,373 | -540 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 64 | 55 | 57 | 67 | 68 | 89 | 98 | 110 | 94 | 79 | 80 | 94 |
Inventory Days | 234 | 191 | 184 | 175 | 158 | 193 | 211 | 208 | 207 | 246 | 245 | 197 |
Days Payable | 117 | 103 | 123 | 125 | 154 | 165 | 167 | 149 | 152 | 168 | 141 | 123 |
Cash Conversion Cycle | 181 | 142 | 119 | 118 | 71 | 116 | 142 | 169 | 149 | 158 | 184 | 168 |
Working Capital Days | 58 | 63 | 46 | 56 | 46 | 62 | 95 | 99 | 79 | 95 | 111 | 108 |
ROCE % | 24% | 18% | 18% | 23% | 29% | 16% | 18% | 15% | 12% | 15% | 15% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
24 May - Transcript of the Post Results Earnings Call held on May 18, 2023
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 May - Newspaper cutting with regard to publication of extracts of audited financial results for the quarter / year ended on March 31, 2023 in Financial Express …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
18 May - The audio recording of the Company's Investor Call discussing about the financial results for the quarter / year ended March 31, 2023 is available on …
- Related Party Transactions 18 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
18 May - Compliance under regulation 24A of SEBI (LODR) Regulations, 2015
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Mar 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Jul 2019Transcript PPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jun 2018Transcript PPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
May 2016Transcript PPT
One of the top five pharmaceutical companies in India.[1]